Navigation Links
Hologic To Provide Business Update at Investor Meeting
Date:1/12/2009

ciated economic downturn; the Company's reliance on third party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement; the Company's ability to integrate its acquisitions and business combinations effectively; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; manufacturing risks, including the Company's reliance on a single source of supply for key components, and the need to comply with especially high standards for the manufacture of many of its products; the Company's ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the early stage of market development for certain of the Company's products; the risk of adverse events and product liability claims; risks related to the use and protection of intellectual property; expenses and uncertainties relating to litigation; technical innovations that could render products marketed or under development by the Company obsolete; competition; general future legislative, regulatory, or tax changes; the risks of conducting business internationally, including the effect of exchange rate fluctuations on those operations; financing risks, including the Company's obligation to meet financial covenants and payment obligations under the Company's financing arrangements and leases; and the Company's ability to attract and retain qualified personnel.

The risks included above are not exhaustive. Other factors that could adversely affect the Company's business and prospec
'/>"/>

SOURCE Hologic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Hologic, Inc. to Release First Quarter Fiscal 2009 Operating Results on Monday, February 2, 2009
2. Selflessness, core of all major world religions, has neuropsychological connection
3. Hologic to Present at the J.P. Morgan 27th Annual Healthcare Conference
4. Psychological Counseling Boosts Breast Cancer Outcomes
5. Psychological interventions associated with breast cancer survival
6. Hologic Announces Fourth Quarter and Fiscal 2008 Operating Results
7. Psychological study reveals that red enhances mens attraction to women
8. Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008
9. Gastric cancer with 3 pathological features
10. 9/11s Psychological Scars Slowly Healing
11. Hologic Announces Third Quarter Fiscal 2008 Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 As interest in ... health care gains momentum worldwide, Rev. Eric J. Hall ... Chaplaincy Network (HCCN), will be the keynote speaker on ... in Israel’s public health system. , The conference, “Hope and ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a list ... policy . , Some types of vehicles cannot be covered ... released blog post to see if their vehicle qualifies for auto ... some of the cars that cannot be covered by a plan. ...
(Date:1/22/2015)... January 22, 2015 Step into a ... the Science Museum of Virginia. Wicked Plants, the Museum’s ... Plants unearths 75 poisonous, carnivorous and diabolical plants inside ... room to uncover the biochemical, physical and neurological processes ...
(Date:12/26/2014)... The US represents the largest market for CRC across the ... that sales of branded therapies were $2.23 billion. The US ... of the disease, high drug treatment rate, and higher drug ... of CRC therapies over the forecast period will be driven ...
Breaking Medicine News(10 mins):Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... 2 copies of variant, puffing before age 17 boosted odds ... -- People with certain common genetic variations that affect their ... life-long nicotine addicts if they begin smoking before they turn ... people who begin smoking at a young age are more ...
... NEW YORK, July 17 Fresh Harvest Products,Inc. ... is expanding and,enhancing its long standing commitment to ... offerings, through a new initiative to,build natural and ... side the Fresh Harvest brands,through our network., ...
... A NEW SOUTH AFRICA TO PRODUCE, HACHETTE AUDIO TO ... PROGRAMS SERVING AFRICAN AIDS ORPHANS, LOS ANGELES, July ... week, Artists for a New South Africa (ANSA) announced ... African,Folktales, an award-winning book of legendary tales hand-picked by ...
... Uninsured Fail to Address the High Percentage of people with Mental ... ... July 17, 2008 -- New data indicates that more than one ... or addiction disorder, or both., , , , ,Many state healthcare ...
... France, July 17 - First-Half 2008 Revenue ... Constant Exchange Rates Essilor International, the ... EUR1,520.3 million for the six months,ended June 30, 2008, ... Like-for-like growth was 5.4%, in line with trend rates, ...
... a privately held medical device manufacturer focusing on ... today announced that the company has closed a ... leading venture capital firms active in medical technology. ... Foundation Medical Partners and were joined in the ...
Cached Medicine News:Health News:Gene Mutation Puts Some Kids at Risk for Tobacco Addiction 2Health News:Fresh Harvest Products, Inc. Announces New Brand Initiative 2Health News:Nelson Mandela's Favorite African Folktales to be Produced as Audiobook Featuring Archbishop Tutu, Gillian Anderson, America Ferrera, Whoopi Goldberg, Samuel L. Jackson, Alan Rickman and Jurnee Smollett, Directed by Alfre Woodard 2Health News:Nelson Mandela's Favorite African Folktales to be Produced as Audiobook Featuring Archbishop Tutu, Gillian Anderson, America Ferrera, Whoopi Goldberg, Samuel L. Jackson, Alan Rickman and Jurnee Smollett, Directed by Alfre Woodard 3Health News:Uninsured With Mental Illness and Addiction Disorders Not Covered by State Healthcare Initiatives 2Health News:Essilor - First-Half 2008 Revenue 2Health News:Essilor - First-Half 2008 Revenue 3Health News:Essilor - First-Half 2008 Revenue 4Health News:Essilor - First-Half 2008 Revenue 5Health News:Vertos Medical Inc. Completes Series C Financing 2Health News:Vertos Medical Inc. Completes Series C Financing 3Health News:Vertos Medical Inc. Completes Series C Financing 4
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
(Date:1/23/2015)... Africa , Jan. 23, 2015   Leatt Corporation ... personal protective equipment for all forms of sports, including ... Leatt-Brace® neck brace, announced today that the UISP Lega ... now requires all riders to wear a neck brace ...
(Date:1/23/2015)... China , Jan. 23, 2015 Tianyin Pharmaceutical ... company that specializes in the development and sale of ... generics and active pharmaceutical ingredients (API) today announced the ... (JCM) API operation. 1. Following the September ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), ... from two pre-clinical studies that,provide evidence ... combining nab-paclitaxel (ABRAXANE(R) for Injectable,Suspension (paclitaxel ... VEGF inhibitor drugs like,bevacizumab (Avastin(R)) at ...
... WIRE)--Apr 19, 2007 - Abraxis BioScience,Inc. ... first-time data from a pre-clinical study,evaluating ... nab-rapamycin,(ABI-009), an albumin-bound mTOR kinase inhibitor, ... Research (AACR) Annual Meeting held,April 14-18, ...
Cached Medicine Technology:Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 2Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 3Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 4
For monitoring vacuum pressure, suitable for use with all QIAvac manifolds;...
... Millex Filter Units,Filter units with ... hydrophobic Fluoropore membrane are ideal for ... venting of sterile containers, and for ... sterile 25 mm Millex filter units ...
... Undercounter refrigerator -4C. ... is reversible. Interior light. ... Two see-through drawers. Two ... large bottles. Adjustable thermostat. ...
Designed to meet the requirements of reagent grade water for routine analysis....
Medicine Products: